Dong-A ST announced on Jan. 4 that it has signed a license-in agreement with SK Biopharmaceuticals to license out its new epilepsy drug Cenobamate in 30 countries including Korea, Southeast and Southwest Asia, Russia, Australia, New Zealand, and Turkiye.
Under the agreement, Dong-A ST will receive drug product production technology from SK Biopharmaceuticals to supply Cenobamate to the 30 countries and will be responsible for licensing, selling, and producing Cenobamate in those 30 countries.
Dong-A S.T. plans to launch Cenobamate in Korea in 2026 with benefit listing. It will also pursue approval and supply in 29 other countries, including East and Southwest Asia, Russia, and South Africa.
“We look forward to becoming a partner that can supply Cenobamate, an innovative new drug recognized for its outstanding efficacy to patients in Korea and other countries as quickly and reliably as possible,” said Lee Dong-hoon, president of SK Biopharmaceuticals.
“We will continue to work closely with SK Biopharmaceuticals to ensure the early supply of Cenobamate, a highly effective new drug for epilepsy, to satisfy epilepsy patients who have waited for the drug for a long time,” said Kim Min-young, president of Dong-A ST. “We will do everything we can do to supply it to 30 countries including Korea as soon as possible.”